Short-term and longer-term effects of brivaracetam on cognition and behavior in a naturalistic clinical setting—Preliminary data


Brivaracetam (BRV) was approved in 2016 as a new antiepileptic drug (AED) for the adjunctive pharmacological treatment of focal-onset seizures with or without secondary generalization. Meanwhile BRV was also approved as monotherapy. BRV is a derivative of levetiracetam (LEV) with a 15- to 30-fold higher affinity to ubiquitous synaptic vesicle glycoprotein 2A [1].


Leave A Reply